Moderna expands use of AI-ready R&D platform
Ella Day | May 12, 2025 | News story | Business Services, Research and Development, Technical Consultancy | AI, Benchling, Corporate, Moderna, R&D, digital transformation
Moderna has expanded its partnership with Benchling, a cloud-based research platform, to support its broader research organisation. Previously used by its technical teams, the platform will now be adopted by scientists across the company as part of efforts to streamline data management and accelerate research workflows.
The move reflects a wider shift in the biotech sector towards integrated digital systems capable of supporting artificial intelligence (AI)-driven research. Benchling allows scientists to design experiments, track samples and analyse data within a single platform, replacing a patchwork of legacy tools. This transition is intended to reduce set-up time for new workflows, enable high-throughput data processing, and standardise information for machine learning applications.
“AI is creating extraordinary opportunities in science, but realising its full potential requires entirely new ways of working,” said Wade Davis, senior vice president at Moderna. “Through this collaboration, our scientists have access to a strong foundation for AI and our computational scientists and engineers are empowered to do truly cutting-edge work.”
Benchling’s platform has also been adopted by other pharmaceutical companies, including Sanofi, AstraZeneca and Zealand Pharma to help digitise and automate aspects of R&D.
“Moderna and Benchling are showing what the future of R&D looks like – fully digital, deeply integrated and built for intelligence and scale,” said Sajith Wickramasekara, CEO and co-founder of Benchling.
Ella Day
12/5/25
Related Content
Agentic commercial: how AI creates dialogue with HCPs and patients to help medicines reach them faster
By Chris Moore Commercial engagement in biopharma used to centre largely on direct conversations between …
Liverpool launches £20m lab for infectious disease drug discovery
A new £20m high-security laboratory using robotics, artificial intelligence (AI) and human organoids to accelerate …
AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …
